Last year the FDA committed to holding a Stakeholder Meeting about drug development and treatment for ME(cfs).
Originally planned for one day, the meeting will now be 1.5 days long and will begin on the afternoon of Thursday April 25th and go all day Friday April 26th.
Here is what is available on the FDA website (http://www.fda.gov/Drugs/NewsEvents/ucm319188.htm):
“FDA Workshop on Drug Development for Chronic Fatigue Syndrome (CFS)
and Myalgic Encephalomyelitis (ME) – Update
The public workshop will be held on the afternoon of April 25 and all day, April 26, at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814, Phone 301-897-9400.
Beginning at 1:00 pm on April 25, FDA will gather patients’ perspectives on CFS and ME through a facilitated group discussion focusing on two main topics: (1) disease symptoms and daily impacts that matter most to patients; and (2) patients’ perspectives on current approaches to treating CFS and ME.
The second day will include a scientific discussion with patients, clinicians, researchers and government experts focusing on how to identify quantitative outcome measures to determine if disease symptoms improve with specific drug interventions.
Additional information will be posted soon (see link below), including the Federal Register Notice that will describe the meeting format and provide details about how to register to attend the meeting.”